NATICK, Mass., Oct. 27, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) introduces its CardioTeach™ iPad® app, an industry-first, free educational resource to help healthcare professionals better educate patients and caregivers about therapy options related to cardiovascular and peripheral diseases, specifically atrial and ventricular arrhythmias, coronary artery disease, heart failure, heart rhythm disorders and peripheral vascular disease.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/43509-boston-scientific-cardioteach-ipad-app  

(Photo: http://photos.prnewswire.com/prnh/20111027/MM93070)

CardioTeach provides an overview of normal heart function and common coronary, rhythm and peripheral vascular conditions.  Graphics and easy-to-understand content enable a healthcare provider to effectively explain specific disease states and review available treatments and procedures with patients and their families, enabling them to make more informed decisions about their health.

CardioTeach's easy-to-use features allow physicians to:

• Customize and annotate anatomical illustrations
• Overlay cardiac devices, such as pacemakers and lead wires, onto anatomical illustrations
• Add notes for emphasis, clarification or personalization
• Email completed graphics and information to patients, caregivers or other healthcare professionals

"Most medical device apps are designed to educate physicians on a specific product or therapy.  CardioTeach is unique because it lets clinicians better educate patients about their overall heart and vascular health and available treatment options," said Leslie Saxon, M.D., Chief of Cardiovascular Medicine at University of Southern California.  "I like CardioTeach because it allows patients to have something they can reference after they leave my office and when thinking about or explaining what went on during the office visit.  It also allows my patients and families to educate themselves prior to and between visits."

"A recent study shows that one in five physicians use a tablet computer in their practice.  Creating an app that enables healthcare professionals to use this technology to enhance communication with patients and caregivers is a logical extension of our efforts to empower patients with information about Boston Scientific's therapies," said Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management for Boston Scientific.  "As part of our commitment to patient education, Boston Scientific designed this comprehensive app to be available at no charge in the Apple App Store."

"Boston Scientific is an industry leader in the deployment of iPads to its U.S. sales force," said Rich Adduci, Senior Vice President and Chief Information Officer for Boston Scientific.  "In August, the Company launched its Neuromodulation Learning Institute™ app, the industry's first educational resource for healthcare providers using spinal cord stimulation to manage chronic pain suffered by their patients.  Today's announcement further demonstrates our dedication to using innovative technologies in new ways to deliver leading-edge information and services to healthcare customers and their patients."

Visit www.CardioTeach.com for additional information about CardioTeach™ for the iPad®.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding new technology introductions and CardioTeach performance.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new technology introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

SOURCE Boston Scientific